A detailed history of Quest Partners LLC transactions in Cullinan Oncology, Inc. stock. As of the latest transaction made, Quest Partners LLC holds 20,404 shares of CGEM stock, worth $336,257. This represents 0.03% of its overall portfolio holdings.

Number of Shares
20,404
Previous 2,039 900.69%
Holding current value
$336,257
Previous $35.6 Million 860.53%
% of portfolio
0.03%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

BUY
$16.03 - $20.86 $294,390 - $383,093
18,365 Added 900.69%
20,404 $342 Million
Q2 2024

Aug 06, 2024

SELL
$15.63 - $29.35 $103,845 - $195,001
-6,644 Reduced 76.52%
2,039 $35.6 Million
Q1 2024

May 09, 2024

SELL
$10.17 - $19.02 $90,696 - $169,620
-8,918 Reduced 50.67%
8,683 $148 Million
Q4 2023

Feb 09, 2024

BUY
$7.89 - $10.23 $138,871 - $180,058
17,601 New
17,601 $179 Million

Others Institutions Holding CGEM

About Cullinan Oncology, Inc.


  • Ticker CGEM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,612,200
  • Market Cap $752M
  • Description
  • Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...
More about CGEM
Track This Portfolio

Track Quest Partners LLC Portfolio

Follow Quest Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Quest Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Quest Partners LLC with notifications on news.